Logo

Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis

Share this
Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis

Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis

Shots:

  • The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks.
  • The therapy has shown similar efficacy and safety profile of CT-P13 IV and provides patients an opportunity of self-administration to control their own treatment
  • The company applied patent protection until 2038 for Remsima SC in ~ 100 countries throughout North America- EU and Asia and will be the first product to enter the Canadian market

 ­ Ref: Newswire Canada | Image: CBIZ

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions